银屑病药物托法替尼的治疗效果和服用剂量

Introduction: Tofacitinib is a Janus kinase (JAK) inhibitor used to treat autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis (UC). Tofacitinib is a drug developed by Pfizer. This article mainly talks about the therapeutic effect, side effects treatment, usage and dosage, medication for special groups, precautions, etc. of tofacitinib.

Therapeutic effect

Tofacitinib has shown good efficacy in the treatment of rheumatoid arthritis. A multicenter, double-blind randomized controlled trial showed that for patients with rheumatoid arthritis who had an inadequate response to DMARDs (anti-rheumatic drugs), treatment with tofacitinib significantly improved the percentage of patients who achieved a 20% improvement in rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria (ACR20). This indicates that tofacitinib has a significant therapeutic effect in the treatment of rheumatoid arthritis.

Tofacitinib has also shown certain efficacy in the treatment of ulcerative colitis (UC) and psoriasis. By inhibiting cytokine signaling related to the JAK pathway, tofacitinib can reduce the inflammatory response and improve patients' symptoms. Tofacitinib has shown potential therapeutic potential in patients with refractory moderately to severely active UC. Within 1 year of treatment, approximately 41% of patients can achieve sustained clinical remission

Side Effect Management

Although tofacitinib has shown good efficacy in treating a variety of inflammation-related diseases, patients also need to pay attention to its possible side effects when using it. Common side effects include infections (such as upper respiratory tract infection, nasopharyngitis, urinary tract infection, etc.), laboratory abnormalities (such as lymphopenia, neutropenia, elevated liver enzymes, etc.), and malignant tumors. When using tofacitinib, patients need to do it under the guidance of a doctor and undergo relevant examinations and monitoring regularly.

Medication Reference

The recommended dose of tofacitinib tablets is 5mg, taken 2 times a day, 1 tablet each time. That is to say, take 5mg once in the morning and evening. Administer orally, with or without food. Do not crush, split, or chew tablets; swallow tablets whole. It is best to take it at the same time every day to ensure stable efficacy. If you have any questions or discomfort, you should consult your doctor or pharmacist in time.

Usage in special populations

Pregnancy: There are no sufficient and appropriate controls for teratogenicity trials, so it is recommended that lactating women should only use tofacitinib when the potential benefits outweigh the potential risks.

Children: The safety and effectiveness of tofacitinib in pediatric patients have not been established.

Liver or kidney damage: For those with mild damage, no dosage adjustment is required; for those with moderate or severe damage, the dosage should be adjusted to 5 mg once a day.

Precautions

Tofacitinib may increase the risk of serious infections, including opportunistic infections such as herpes zoster and tuberculosis. When tofacitinib treats people at high cardiovascular risk, the risk of MACE (major adverse cardiovascular events) and cancer is significantly higher than that of TNF inhibitors. During use, regular blood tests are required to monitor blood cell counts, liver function and other indicators that may be affected by the drug.

The commonly used clinical preparations of tofacitinib are tablets, such as tofacitinib citrate tablets, which can be used in combination with methotrexate or other non-biological DMARD drugs. It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.